Abbott intends an NDA on a meta analysis.

Abbott intends an NDA on a meta – analysis, pooled data from two large randomized, controlled clinical trials of a total population of patients with Xinlay of 1,097 examined to make. The intention treat analysis showed a delay in time to disease progression . In men with metastatic, hormone-refractory prostate cancer who took the drug compared to those taking placebo.

It is currently in its second phase III study in men with hormone-refractory prostate cancer that has not spread . It is also evaluated in a Phase II trial in hormone – naive men with rising prostate – specific antigen following prostate cancer surgery. In addition, Abbott Xinlay is in other types of cancer research, including renal, ovarian, brain and non – small cell lung cancers.. Xinlay has been studied in phase II and phase III studies in patients with metastatic, hormone-refractory prostate cancer.1) Cancerbackup is the only one national charity, with the provision out of information on all kinds. Has specialized cancer.

‘wish is the CCG really, hold the government to account,’says Joanne Rule, Cancerbackup boss ‘We are concerned that PCT swift steps towards effective operation and to. Job with and advice from the Cancer Networks ‘She added: ‘. We especially pleased improving implementation of these proposals provide information to patients ‘.